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Blood Pressure Treatment in Kidney Transplant 
Recipients—Can We Improve?
Mari O. Onsøien,1 Karsten Midtvedt, MD, PhD,2 Anna V. Reisæter, MD, PhD,2,3  
Knut Aasarød, MD, PhD,3,4 Bård Waldum-Grevbo, MD, PhD,3,5 Bjørn Egil Vikse, MD, PhD,3,6,7  
Bjørn Odvar Eriksen, MD, PhD,3,8 and Anders Åsberg, PhD2,3,9
Kidney transplantation (KTx) is the preferred treatment for patients with kidney failure, leading to increased 
patient survival and improved quality of life compared with 
dialysis.1-5 Despite successful transplantation, cardiovascular 
(CV) disease remains the leading causes of increased mortality 
and the main nonimmunological reason for graft loss.6,7
Posttransplant hypertension is common with a reported 
prevalence of 50%-90%,8-10 and an important risk factor for 
CV complications and reduced graft function.11,12
Observational studies by Opelz and Döhler13 reported 
a stepwise improvement in both graft and patient survival 
associated with lower blood pressure (BP). A similar ten-
dency was reported for systolic BP by Carpenter et al14 who 
assessed the possible association between BP and CV disease 
in a post hoc analysis of participants in the Folic Acid for 
Vascular Outcome Reduction In Transplantation trial. They 
found that each 20-mm Hg increase in systolic BP was asso-
ciated with a 32% increase in the risk of CV events.
A consensus on a specific BP target for KTx recipients has, 
however, not been clearly specified.15,16 Based on the available 
literature, the Norwegian Renal Registry (NRR) has adapted 
the Kidney Disease Improving Global Outcomes (KDIGO) 
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Kidney Transplantation
Background. Hypertension in kidney transplant (KTx) recipients is common, affecting both patient and graft survival. 
Annual data from the Norwegian Renal Registry reveal that <50% of adult (>18 y) KTx recipients reach target blood pressure 
(BP) ≤130/80 mm Hg. The aim of this study was to identify the determinants of failure to achieve BP control. Methods. 
In conjunction with the 2018 annual data reporting, additional questions were added for recipients with BP >130/80 mm Hg 
(treating physician´s target BP for each patient, reasons for not achieving target, method of measurement). Results. 
Annual forms were received from 98% (3407 of 3486) of KTx recipients, with 1787 (52%) reporting a BP >130/80 mm Hg 
(“above-target” group). These recipients were older, mostly male, with higher body mass index and serum creatinine levels 
(P < 0.05) compared with patients with controlled hypertension (“on-target” group). Valid survey answers were available for 
84% of the “above-target” group (Survresp) with no significant demographic differences versus nonresponders (Survnonresp). 
Among Survresp, 32% were under antihypertensive dose titration, whereas dose-limiting side effects were reported in 7%. 
Target BP was confirmed to 130/80 mm Hg for 60% of Survresp. In recipients for whom the treating physician set target BP 
>130/80 mm Hg, 51% did not reach these individual targets. The number of antihypertensive drugs was significantly higher 
in the “above-target” group versus “on-target” group (mean 2.1 ± 1.2 versus 1.8 ± 1.3) and 36% versus 25% used ≥3 antihy-
pertensive drugs (P < 0.05). Automatic attended BP measurement was utilized by 51%. Conclusions. In KTx recipients, 
a higher BP target achievement seems possible, potentially in the range of 75%-80%.
(Transplantation Direct 2021;7: e688; doi: 10.1097/TXD.0000000000001142. Published online 25 March, 2021.)
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guideline BP target of ≤130/80 mm Hg for adult (>18 y) KTx 
recipients.17 The NRR is a national medical quality registry 
designed to facilitate optimized treatment for all KTx recipi-
ents in Norway. The NRR has set the overall target of 80% 
of patients to achieve the guideline BP, accepting that some 
patients will not reach the BP target (drug side effects, resist-
ant hypertension, nonadherence).
Historically the target BP goal has been achieved by <50% 
of patients in the NRR (Figure 1).18 Therefore, in the 2018 
return, a short survey focusing on recipients with BP >130/80 
mm Hg was distributed (Figure 2) along with the annual cap-
ture of individual data by the NRR. The aim of this project 
was to understand treatment decisions and determine the rea-
sons for failure to achieve the BP target.
MATERIALS AND METHODS
As a national medical registry, the NRR collects data on 
all KTx recipients in Norway on an annual basis. The 
NRR has complete coverage of all kidney transplants 
in Norway since the late 1960s and annual data has 
been collected since 1994. The annual reports are col-
lected on paper forms and include information regarding 
complications, current medication (eg, immunosuppres-
sive drugs, antihypertensives, antithrombotics), clinical 
chemistry, weight, BP, and rejection episodes for each 
individual patient. Data from the last consultation of the 
year are reported to the registry by the treating physi-
cian. BP should be measured according to center practice, 
with the recommended value being mean of the second 
and third measurements following a 5-min rest period. 
Proteinuria was defined as albumin to creatinine ratio 
(ACR) >30 mg/g and/or protein to creatinine ratio (PCR) 
>50 mg/g. In recent decades the response rate for annual 
data has been 96% to 98% and in conjunction with the 
capture of annual data for 2018, additional informa-
tion was requested for recipients with a systolic BP >130 
mm Hg and/or diastolic BP >80 mm Hg.
This was a quality assessment study for the NRR, approved 
by the hospital Data Protection Officer.
The Survey
The survey, together with the annual forms, was distributed 
by mail to the reporting centers in January 2019. They were to 
be answered and returned by April 1, 2019. Survey questions 
are presented in Figure 2. The survey also included a free-text 
field for general comments.
Statistical Analysis
Survey-information was tabulated and descriptive sta-
tistics were performed using the Statistical Package for the 
Social Sciences version 26.0.0.1 (IBM Corp, Armonk, NY). A 
2-tailed P value of <0.05 was considered statistically signifi-
cant. Data are presented as mean and SD or 95% confidence 
interval.
RESULTS
By the end of 2018, there were a total of 3486 adult (>18 
y old) KTx recipients alive with functioning grafts. The 
overall response rate in the 2018 annual return was 98% 
(3407 of 3486) (Figure 3). The population demographic and 
clinical characteristics are shown in Table 1. Fifty-two percent 
(1787 of 3407) of the recipients had a BP >130/80 mm Hg, 
representing the study population for which additional survey 
data were requested. The BP survey response rate was 84% 
(1500 of 1787) (Survresp); the 287 recipients with BP >130/80 
mm Hg for whom no survey data were received are referred 
to as Survnonresp.
The “above-target” patients (n = 1787) were significantly 
older, more often male, with higher body mass index (BMI) 
and serum creatinine compared with the “on-target” patients 
(n = 1620) (Table  1) and with more recent transplants. As 
anticipated, the “above-target” patients were prescribed 
higher number of antihypertensive agents and the use of angi-
otensin-converting-enzyme inhibitors (ACEis) or angiotensin 
FIGURE 1. Kidney transplant recipients in the Norwegian Renal Registry with blood pressure ≤130/80 mm Hg by reporting y.
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receptor blockers (ARBs) was greater than in the “on-target” 
group (Table 1). Diabetes before transplantation was present 
in 18% in the “above-target” group versus 17% in the “on-
target” group (Table  1). ACR and/or PCR was reported in 
92% of patients; 17% of the entire cohort had proteinuria, 
21% in the “above-target” group compared with 13% in the 
“on-target” group (P < 0.001). Patients treated with ACEi/
ARB were more likely to have proteinuria (21% versus 14%; 
P < 0.001) with the highest use being in the “above-target” 
group (23%). There were no significant demographic dif-
ferences of importance for the development of hypertension 
between the Survresp versus Survnonresp groups (Table 1).
Mean BP for the “above-target” group was 140 ± 13/82 ± 9 
mm Hg with systolic BP ranging from 109 to 220 mm Hg 
and diastolic from 49 to 118 mm Hg. Elevated systolic and 
diastolic pressure (>130/>80 mm Hg) were present in 40% 
(603 of 1500) (Table 2).
Individual BP targets were reported for 94% (1413 of 1500) 
of the Survresp patients. In 60% (847  of  1413), the treating 
physician reported 130/80 mm Hg as the target BP. Some 
reported isolated lower systolic (4%) or diastolic (5%) target 
BP. The remaining 36% (n = 504) reported a higher target BP, 
and 51% (256  of  504) of these patients did not reach this 
higher treatment target. The 2 main reasons given by treating 
physician reporting a higher individual BP target were side 
effects from antihypertensive medication (27%) and postural 
hypertension (20%).
For 82% of the patients with a reported BP target 
(1162  of  1413), the treating physicians stated a lower indi-
vidual target than the patients’ actual reading. One-third of 
the Survresp patients (485 of 1500) were under active antihy-
pertensive dose titration (Table 2). In the Survresp patients not 
undergoing dose titration, the main reason for not intensifying 
the treatment was that the reported BP was not representative 
FIGURE 2. The survey issued by the Norwegian Renal Registry should be answered for patients with a measured systolic blood pressure >130 
mm Hg and/or a diastolic blood pressure >80 mm Hg.
FIGURE 3. Flowchart over the submission of annual data from adult (>18 y) kidney transplant recipients to the Norwegian Renal Registry and 
survey response in 2018. Survnonresp, survey nonresponders for “above-target” group; Survresp, survey responders for “above-target” group.
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of the patient´s average BP during preceding year (28%, 
427 of 1500) and 24% (361 of 1500) reported other causes; 
for 136 patients, the physicians considered the patients BP 
as adequate (78 of these patients had a BP <135/85 mm Hg), 
28 had comorbidities limiting treatment, and 22 patients had 
“white coat” hypertension (Table  2). Postural hypotension 
(10%, 154  of  1500), other side effects of antihypertensive 
drugs (7%, 105 of 1500), and nonadherence (4%, 62 of 1500) 
were also reported as reasons for the decision not to up-titrate 
antihypertensive therapy.
On average, patients´ in the Survresp group used 2.1 antihy-
pertensive agents (Table 1): 75% (1121 of 500) were on 1-3 
antihypertensive drugs, 36% (538 of 1500) used ≥3 agents, 
and 9% (134 of 1500) were not using any antihypertensive 
medication (Table 1).
Direct automatic measurement of BP was most frequently 
method of BP monitoring (51%, 773  of  1500), whereas 
manual measurement was conducted by 31% (460 of 1500). 
Automatic, nonattended measurement was performed by 
10% (150 of 1500) and ambulatory 24-h BP was the main 
method reported by 3% (42 of 1500).
The majority in the Survresp group were on triple immu-
nosuppression with calcineurin inhibitors (CNIs; tacrolimus 
or cyclosporine) (93%), mycophenolate (83%), and pred-
nisolone (98%) (Table  1). Three agent immunosuppression 
including CNI was reported for 74% (1196 of 1620) of the 
“on-target” group and 70% (201  of  287) of the Survnonresp 
group. There were no statistically significant differences in 
immunosuppressive medication between the “on-target” 
and the “above-target” group. However, the usage of statins 
was somewhat higher in the “above-target” group; 74% 
(1103 of 1500) versus 70% (1132 of 1620) (P = 0.015).
Any CV complication, specified as myocardial infarction, 
stroke, coronary surgery, percutaneous coronary intervention, 
or other heart surgery during the preceding year is part of 
the annual data reported to the NRR. In 2018, there were a 
total of 291 reported CV events; 11% (167 of 1500) in the 
“above-target” group versus 8% (124 of 1620) in the “on-
target” group (P = 0.077) (Table 1).
DISCUSSION
Our national registry survey on KTx recipients’ shows that 
52% did not reach BP target (set by the registry at ≤130/80 
mm Hg) in 2018. If 1 includes individualized BP targets 
reported in the survey, the overall target achievement was 
55% and excluding those under dose titration resulted in 
63% achieving their target BP. Given that hypertension is an 
established risk factor for CV events and graft survival, it was 
surprising that only one-third of the “above-target” group 
was under active antihypertensive dose titration and 9% were 
actually not on any antihypertensive drugs.
The lack of randomized controlled trials of “optimal BP 
target” in KTx recipients was recognized by KDIGO when 
they set a BP target of ≤130/≤80 mm Hg17 and recommended 
lower target in patients with proteinuria. Data from publi-
cations focusing on posttransplant hypertension and registry 
data indicate that a minority of KTx recipients achieve the 
TABLE 1.
Demographic and clinical characteristics of kidney transplant study population by the end of 2018
Variable All (n = 3407) “On-target” (n = 1620)
“Above-target” (n = 1787)
P Survresp vs Survnonresp P on-target vs SurvrespSurvresp (n = 1500) Survnonresp (n = 287)
Age (y) 58 ± 14 57 ± 15 59 ± 14 59 ± 14 0.70 0.008
Male gender 2185 (64) 1009 (62) 988 (66) 188 (66) 0.91 0.03
BMI (kg/m2) 27 ± 5 26 ± 5 27 ± 5 27 ± 5 0.99 0.001
Years after Tx 10.4 ± 8.1 10.8 ± 8.5 9.9 ± 8.0 10.4 ± 8.1 0.36 0.002
Immunosuppression
 Tacrolimus 2117 (62) 998 (62) 948 (63) 171 (60) 0.25 0.54
 Cyclosporine A 1029 (30) 490 (30) 449 (30) 90 (31) 0.63 0.96
 Mycophenolate 2769 (81) 1311 (81) 1238 (83) 220 (77) 0.03 0.62
 Prednisolone 3342 (98) 1594 (98) 1467 (98) 281 (98) 0.91 0.22
 Othera 457 (13) 222 (14) 183 (12) 52 (18) 0.15 0.21
Antihypertensives 1.9 ± 1.3 1.8 ± 1.3 2.1 ± 1.2 2.0 ± 1.3 0.30 <0.001
 0 417 (12) 256 (16) 134 (9) 27 (9) 0.80 <0.001
 1 891 (26) 454 (28) 359 (24) 78 (27) 0.26 0.02
 2 896 (26) 395 (24) 418 (28) 83 (30) 0.72 0.02
 3 674 (20) 275 (17) 344 (23) 55 (19) 0.14 <0.001
 ≥4 369 (11) 139 (9) 194 (13) 36 (12) 0.86 <0.001
 Missing 160 (5) 101 (6) 51 (3) 8 (3)   
 ACEi/ARB 1450 (43) 640 (40) 694 (46) 116 (40) 0.08 0.001
P-creat (μmol/L) 130 ± 63 126 ± 58 135 ± 68 131 ± 66 0.38 <0.001
Proteinuriab 537 (17) 195 (13) 289 (21) 53 (20) 0.85 <0.001
 Missing 282 (8) 144 (9) 112 (7) 26 (9)   
Complicationsc 291 (9) 124 (8) 162 (11) 5 (2) <0.001 0.08
aOther immunosuppression: azathioprine, everolimus, sirolimus, and belatacept.
bProteinuria defined as ACR >30 mg/g and/or PCR >50 mg/g.
cComplications = myocardial infarction, stroke, coronary surgery/PCI, and other heart surgery.
Data are presented as mean ± SD and n (%).
ACEi, angiotensin-converting-enzyme inhibitor; ACR, albumin to creatinine ratio; ARB, angiotensin receptor blocker; BMI, body mass index; PCI, percutaneous coronary intervention; PCR, protein to 
creatinine ratio; P-creat, plasma creatinine; Surv
nonresp
, survey nonresponders for “above-target” group; Surv
resp
, survey responders for “above-target” group; Tx, transplantation.
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KDIGO BP target.8,18,19 There are several other international 
hypertension guidelines advocating a more relaxed BP target 
for nonproteinuric patients with chronic kidney disease of 
<140 mm Hg.20,21 However, even with this target, 36% of our 
hypertensive KTx recipients had a systolic BP >140 mm Hg 
raising the question why nephrologists involved in renal 
transplant management appear to settle for a higher-than-rec-
ommended BP for many patients? It is possible that treating 
physicians accept reaching either the systolic or the diastolic 
BP target level (if the other is fairly close) and, in support of 
this notion, only 40% of patients who did not reach the BP 
goal failed to reach both systolic and diastolic goal.
The current study reveals that the recipients in the “above-
target” group were significantly older (59 ± 14 versus 57 ± 15 
y; P < 0.05), more likely to be male, with a higher BMI and 
serum creatinine when compared with the “on-target” group. 
These are all traditional risk factors for the development 
of hypertension and confirm previous reports in transplant 
patients.8,10,11 In 56% of cases, the reporting physicians con-
firmed use of the NRR target BP ≤130/≤80 mm Hg. In 36% 
of responses, the treating physician set a higher individual 
target BP than 130/80 mm Hg, despite which 51% of their 
KTx recipients failed to reach the higher treatment target. 
Overall, 82% (1162  of  1413) of the Survresp group had a 
reported BP the treating physician considered “not accepta-
ble.” Despite this, only one-third of patients were under active 
antihypertensive dose up-titration and the mean number of 
antihypertensive drugs was only 2.1. Furthermore, 9% of the 
“above-target” recipients did not receive any antihypertensive 
drug therapy. These data suggest that more KTx recipients 
may reach their BP target simply by increasing the prescrip-
tion of antihypertensive medication.
In the Survresp group, 30% (538 of 1500) used ≥3 antihyper-
tensive agents and are therefore classified as treatment resist-
ant.22,23 In this group, the median age was 62 y (ranging from 
20 to 85 y), 70% were male, the BMI was 28 (16-53) kg/m2, 
and serum creatinine level 152 ± 80 μmol/L. With regard to BP 
in the patients with resistant hypertension, 55% had a systolic 
BP ≥140 mm Hg and 17% had a diastolic BP ≥90 mm Hg. 
In this subgroup, improved BP is, if possible, strongly recom-
mended.13,24 The reasons for not increasing antihypertensive 
therapy in the present study include in 24% (127 of 538) the 
statement that the measured BP was not representative for 
the patients’ average BP, postural hypotension limiting dose 
escalation in 13% (72 of 538), limiting side effects in 10% 
(56 of 538), and poor adherence in 9% (20 of 538). Overall, 
these patients account for 16% of the survey population and 
provide an acceptable reason for setting the target for achiev-
ing BP target level of 80% of the total population, a strategy 
common in most published guidelines.
It is generally recognized that optimal BP control is more 
important than the use of a specific choice of antihypertensive 
drug class.8 In the registry, we have information on the usage 
of ACEi or ARBs, drugs that have established nephron-protec-
tive and antiproteinuric effects in nontransplant populations. 
In a KTx recipient, specifically in the early postoperative 
phase, the introduction of blockers of the renin-angiotensin 
system is often associated with a reduction in glomerular fil-
tration rate, which may be misinterpreted as a rejection epi-
sode, which may limit the use. However, in the maintenance 
phase following transplantation, ACEi/ARBs are excellent 
antihypertensive drugs with few patient-reported side effects. 
Overall, in our adult KTx study population, the mean number 
of antihypertensive drugs was 1.9 ± 1.3 with only 12% not 
requiring antihypertensive therapy. As expected, the Survresp 
were in need of significantly more antihypertensive drugs 
than the “on-target” group. Moreover, there was a higher 
prevalence of ACEi/ARB usage in the “above-target” group 
compared with the “on-target” group (P = 0.001). Data were 
available on the presence or absence of proteinuria (defined as 
ACR <30 and/or PCR >50) in 92% of the patient with 16% 
reporting the presence of proteinuria. There were significantly 
more patients with proteinuria in the “above-target” (21%) 
versus “on-target” group (13%). The highest prevalence of 
treatment with an ACEi or an ARB was in the “above-target” 
group (23%), consistent with an active selection of these drug 
classes in patients with proteinuria. Unfortunately, the survey 
has no data on other antihypertensive drug classes.
In an attempt to optimize any drug treatment, identifying 
patients with adherence problems is important. In KTx recipi-
ents, a degree of nonadherence towards immunosuppressive 
medication is reported to be in the range of 30%-35% and 
similar findings are likely for antihypertensive medication.25 
Several factors can contribute to nonadherence; hypertension 
is asymptomatic and medication has side effects, low health 
literacy, polypharmacy, forgetfulness, and poor physician-
patient relationship (including the failure to consider nonad-
herence).26 Low adherence was, however, only reported for 
4% in the Survresp group, which we believe reflects underre-
porting by the treating physicians. Adherence rates have a ten-
dency to fall when the number of drugs increase and higher 
TABLE 2.
Survey results on measured blood pressure, method of 
measurement, antihypertensive dose titration, and cause 
of no antihypertensive dose titration in the “above-target” 
group with survey response (Survresp)
Survey variable Survresp (n = 1500)
Measured blood pressure
 Systolic blood pressure (mm Hg) 109-220 mm Hg (139.8 ± 13.0)
 Diastolic blood pressure (mm Hg) 49-118 mm Hg (82.2 ± 9.2)
 Elevated systolic and diastolic blood pressurea 603 (40)
 Isolated elevated systolic blood pressurea 565 (38)
 Isolated elevated diastolic blood pressurea 329 (22)
Method of blood pressure measurement
 Manual 460 (31)
 Automatic attended 773 (51)
 Automatic nonattended 150 (10)
 24-h ambulatory 42 (3)
 Missing 75 (5)
Antihypertensive dose titration
 Yes 485 (32)
 No 981 (65)
 Missing 34 (2)
Cause for no antihypertensive dose titration
 Registered blood pressure not representative 427 (28)
 Adherence 62 (4)
 Side effects 105 (7)
 Postural hypotension 154 (10)
 Other 361 (24)
aAccording to guidelines ≤130/80 mm Hg.
Data are presented as range, mean ± SD, and n (%).
Surv
resp
, survey responders for hypertensive patients (n = 1500).
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adherence to antihypertensive medication has been associated 
with improved BP control.27 Regular feedback, patient educa-
tion, frequent clinic visits, and medication reminder packag-
ing has been shown to improve adherence.26,28 By performing 
the survey, we increased the physicians’ awareness on BP 
target, and it will be of interest to see whether BP control is 
improved in future surveys.
Our cross-sectional survey revealed that the “above-target” 
group, especially the treatment-resistant subgroup, had a signif-
icantly higher BMI than the “on-target” group. A recently pub-
lished German study (KTx360°) evaluated pre- and post-KTx 
BMI in 433 recipients.29 In the present study, 23% versus 19% 
had a BMI >30 kg/m2 in the “above-target” and “on-target” 
groups, respectively (P = 0.014). Nonpharmacologic interven-
tions such as diet, exercise, and weight reduction (if warranted) 
should always be part of posttransplant hypertension treat-
ment. From a clinical perspective, helping the overweight 
patient with a tailored intervention for weight loss may be even 
more effective than adding additional antihypertensive drugs.
In the survey, automatic witnessed BP measurement was 
registered for 51%, whereas 31% was subjected to manual 
BP measurements. In only 10% of the patients, the physician 
took the time to use automatic nonattended BP measurements. 
A recently published study by Mallamaci et al30 utilizing 24-h 
ambulatory BP monitoring found that “white coat hyperten-
sion” occurred in 12% and masked hypertension in 26% of 
their KTx patients. However, only 3% of treating physicians 
had utilized this method of BP monitoring, this despite the 
fact that 28% of physicians reported that “measured BP is 
not representative for the patient’s average blood pressure.” 
This highlights the need for standardization of BP monitoring, 
specifically to compare registry outcomes.
The survey only detected a tendency towards more CV 
incidence in the hypertensive patients during the last year 
(P = 0.077). If we merge CV incidents for the last 3 y, the rates 
are significantly lower in the “on-target” group (data not 
shown), supporting the case for intensified BP treatment.
Our study has several limitations. BP measurements were not 
standardized and reported only on 1 occasion. It is also a weak-
ness that BP data were reported by the treating physician and 
not blinded. There are no data on smoking, diet (eg, sodium 
intake), or exercise habits. We only have limited information 
on the number of antihypertensive drugs and usage of ACEi/
ARB, and there is limited information regarding the presence 
or treatment of hypertension before transplantation (collected 
since 2016). Information regarding the history of hyperten-
sion in deceased donors is also lacking, although there are data 
from living donors. Our transplant-population is predominantly 
Caucasian and data may not be representative for patients of 
other ethnicities. There was also a very large difference between 
centers in actual BP target achievements ranging from 21% 
to 81% (data not shown). Currently, the registry data cannot 
explain the success of 1 center over another, but this shows the 
potential to improve target achievement. The major strength of 
our study is the annual capture of data from 98% of the total 
national population, with the added strength that all patients 
were transplanted at 1 center with uniform immunosuppressive 
protocols and CNI target trough levels during follow-up.
In conclusion, our data suggest that in KTx recipients, cur-
rent BP control is suboptimal, with potential for improved 
target achievement potentially in the range of 75%-80%. 
Individualized BP targets based on patient´s comorbidities, 
age, and other variables might be beneficial in some recipi-
ents, as may addressing the reasons for failure to up-titrate 
therapy and the standardization of BP monitoring.
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